Jupiter Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Jupiter Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,238	Closed	-$288K	–	570
2022 Q1	$288K	Hold	1,238	–	–	﹤0.01%	484
2021 Q4	$498K	Sell	1,238 -1,139	-48%	-$480K	0.01%	470
2021 Q3	$1.06M	Sell	2,377 -1,672	-41%	-$599K	0.01%	410
2021 Q2	$1.57M	Buy	+4,049	New	+$1.44M	0.02%	402

Other funds holding ATRA

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Jupiter Asset Management's ATRA Position: Q2 2022 in Review

Jupiter Asset Management sold out of Atara Biotherapeutics (ATRA) in Q2 2022, closing a stake of 1,238 shares — an estimated $288K sold.

Jupiter Asset Management first reported a position in ATRA in Q2 2021 and held it in 4 quarters. The position peaked at $1.57M in Q2 2021. 134 funds tracked by Wall St. Rank hold ATRA as of Q2 2022.

Jupiter Asset Management reported no remaining Atara Biotherapeutics position as of Q2 2022 after selling out during the quarter.
Jupiter Asset Management sold 1,238 Atara Biotherapeutics shares in Q2 2022, an estimated $288K.
Jupiter Asset Management first reported a position in Atara Biotherapeutics in Q2 2021 and held it in 4 quarters.
Jupiter Asset Management's Atara Biotherapeutics position peaked at $1.57M in Q2 2021.
134 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2022.

Based on Jupiter Asset Management's 13F filing for Q2 2022, filed 10 Aug 2022.